Bora follows the guidance of the Access to Medicine Index (ATMI), committed to improving drug research and development, accessibility, and affordability. The Company pledges to ensure stable drug supply at reasonable prices to benefit more patients and support the sustainable development of global healthcare systems. We currently do not engage in the development of proprietary new chemical entities (NCEs). Its existing product portfolio primarily consists of FDA 505(b)(2) modified drugs and generic drugs. The pricing of such products is heavily influenced by national regulatory pricing systems, healthcare reimbursement policies, and market competition, leaving the company with relatively limited flexibility in pricing decisions.
Moreover, the current product range does not include treatments for hepatitis C or other major infectious diseases that are among the most urgent healthcare needs in developing countries. As a result, Bora’s access-to-medicine strategy is centered on ensuring stable supply and fair pricing of its existing products, rather than developing new drugs targeting diseases prevalent in the developing world.
Bora’s pharma sales operations are mainly conducted through its subsidiary Upsher-Smith Laboratories, LLC (“Upsher-Smith”), which has long supported rare disease communities through its Promise of Support™ Program. The program provides branded prescription drugs indicated for rare diseases, ensuring comprehensive assistance for patients, caregivers, and healthcare providers throughout the treatment process.
Promise of Support™ Program
Suffering from rare diseases often brings significant challenges. The Promise of Support™ Program is designed as a holistic care system to remove barriers at every step of the treatment journey:
1. Reducing Barriers to Care: Helping patients navigate financial, insurance, and administrative complexities so they can access treatment with less burden.
2. Ensuring Continuous Access: Supporting uninterrupted therapy by assisting patients during coverage transitions, insurance reviews, or other gaps in access.
3. Supporting the Whole Patient: Offering personalized guidance, educational resources, multilingual support, and convenient services that help patients stay informed and engaged in their care.
4. Inspiring Confidence and Hope: Providing tools and resources that empower patients and caregivers as they begin and continue therapy, reinforcing that they are never alone in the process.
Currently, the program primarily focuses on epilepsy and rare neuromuscular diseases.
View our U.S. FDA-approved medicines
Patient Advocacy & Disease Awareness
Beyond drug supply, we actively partner with patient advocacy groups to promote disease education and awareness. In 2025, our key partnerships include Epilepsy Foundation and CURE Epilepsy, TSC Alliance, Parent Project Muscular Dystrophy (PPMD), and Muscular Dystrophy Association (MDA). We actively support initiatives such as “National Epilepsy Awareness Month” to raise public awareness and support the caregiving community.
Drug Donation Project
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Drug Donation Amount | 265,900 | 164,095 | 295,569 |
Responsible Pricing
Bora adheres to the principles of fairness and affordability, implementing a tiered pricing strategy based on the World Health Organization’s National Drug Pricing Policy Guidelines. Pricing considers market characteristics of each country, integrating factors such as GDP and local income levels to improve patient access and affordability, while incorporating local distributors and insurance reimbursement mechanisms to ensure reasonable drug pricing. Its subsidiary Upsher-Smith uses a structured evaluation mechanism, considering clinical benefits, market conditions, manufacturing costs, and competitive dynamics, to determine reasonable list and net prices, and provides patient assistance and copay support through the Promise of Support® Program. In 2025, about 24% of patients taking Upsher-Smith therapies received financial support through the patient assistance program or copay scheme; 86 patients received direct support through the Patient Assistance Program (PAP), and the Company distributed over 1,000 boxes of drugs free of charge.
Strategy for Vulnerable Groups and Unmet Medical Needs
Upsher-Smith is committed to extending the accessibility of essential medicines and actively responding to unmet medical needs, particularly for vulnerable and resource-poor populations. Through continuous communication with medical professionals and patient advocacy organizations and systematic analysis of drug-access challenges in the U.S. healthcare system, Upsher-Smith identifies unmet medical needs to guide its portfolio decisions. A key component of this strategy is the Promise of Support® Program, which includes a Patient Assistance Program (PAP) to help eligible patients obtain medications at reduced or no cost. Upsher-Smith’s portfolio includes brand-name drugs for neurological disorders including epilepsy, tuberous sclerosis (TSC), and Duchenne muscular dystrophy (DMD); in 2025 it continued to supply and market four niche or underserved-indication products: VIGAFYDE®, Vigadrone®, Torpenz®, and Kymbee™.